FDA discusses approval of obesity drugs

FDA officials discussed the development and regulatory process that led to the approval this year of obesity drugs Belviq lorcaserin and Qsymia phentermine/topiramate in an article published in The New England Journal of Medicine. The agency said that while there may be "yet-unknown benefits and risks," both drugs have favorable risk-benefit profiles for chronic weight management in obese and overweight patients. ...